Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

California-based Artera, a company that develops multimodal AI-based prognostic and predictive cancer tests, has been granted de novo authorization by the FDA for its AI tool for prostate cancer ...

ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate ...

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...